GENinCode Shares Rise on FDA Filing for Heart Disease Test Kit
August 16 2023 - 7:41AM
Dow Jones News
By Ian Walker
Shares of GENinCode rose 17% after the company said that it has
filed a premarket notification with the U.S. Food and Drug
Administration for its coronary heart disease risk assessment test
kit, Cardio inCode-Score.
Shares at 1106 GMT were up 2.0 pence at 13.50 pence.
The London-listed predictive genetics company said Wednesday
that approval will enable the expansion and commercial distribution
of the device in the U.S.
It expects to receive FDA approval for the device over the next
six months.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 16, 2023 07:26 ET (11:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Genincode (LSE:GENI)
Historical Stock Chart
From Dec 2024 to Jan 2025
Genincode (LSE:GENI)
Historical Stock Chart
From Jan 2024 to Jan 2025
